Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2025 11:05 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., presents today at the San Antonio Breast Cancer Symposium preclinical studies demonstrating effectiveness of IRX4204, the company’s clinical stage retinoid X nuclear receptor (RXR) agonist compound, for synergistically promoting killing of HER2+ breast cancer cells in combination with HER2-targeted chimeric antigen receptor modified T-cells (CAR-T).

Io Therapeutics announced today data demonstrating effectiveness of its RXR agonist IRX4204 for synergistic killing of HER2+ breast cancer with CAR-T cells
July 09, 2024 20:00 ET | Source: Io Therapeutics, Inc.

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease

Io Therapeutics presented data on the potential of IRX4204 for treatment of aging-related neurodegeneration, Parkinson's disease, and Alzheimer's disease